Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia

Anti-Cancer Drug Design

Volumn 13, Issue 6, 1998, Pages 687-702

  Hodgkiss, Richard J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

2 Nitroimidazole; CCI 103F; EF5; Hypoxia marker; NITP; NMR; PET; Pimonidazole; Predictive assay; SPECT; SR 4544; Tumour hypoxia

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; FLUORESCENT DYE;

CANCER SURVIVAL; CELL LABELING; FLOW CYTOMETRY; HYPOXIA; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; MORBIDITY; OXYGENATION; POLAROGRAPHY; PRIORITY JOURNAL; REVIEW; TISSUE OXYGENATION; TISSUE SECTION; TREATMENT FAILURE; TUMOR;

ANIMALS; BIOLOGICAL MARKERS; CELL DIVISION; CELL HYPOXIA; FLOW CYTOMETRY; HUMANS; NEOPLASMS; NITROIMIDAZOLES; OXIDATION-REDUCTION;

EID: 0031656984     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. ABOAGYE, E.O., LEWIS, A.D., JOHNSON, A., WORKMAN, P., TRACY, M. & HUXHAM, LM. (1995). The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. British Journal of Cancer, 72, 312.
2. ABOAGYE. E.O., LEWIS, A.D., GRAHAM, M.A., TRACY, M., KELSON, A.B., RYAN, K.J. & WORKMAN, P. (1996). The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anticancer Drug Design, 11, 231.
3. ABOAGYE, E.O., MAXWELL, R.J., KELSON, A.B., TRACY, M., LEWIS, A.D., GRAHAM, M.A., HORSMAN, M.R., GRIFFITHS, JR & WORKMAN, P. (1997). Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumour hypoxia. Cancer Research, 57, 3314.
4. ARTEEL, O.E., THURMAN, R G., YATES & RALEIGH, J.A (1995). Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. British Journal of Cancer, 72, 889.
5. BISKUPIAK, J.E., GRIERSON, J.R., RASEY, J.E., MARTIN, G.V. & KROHN, K.A (1991). Synthesis of an (iodovinyl)-misonidazole derivative for hypoxia imaging. Journal of Medicinal Chemistry, 34, 2165-2168.
6. BJORNHEDEN, T., EVALDSSON, M. & WIKLUND, O. (1996). A method for the assessment of hypoxia in the arterial wall, with potential application in vivo. Arteriosclerosis Thrombosis Vascular Biology, 16, 178.
7. BRIZEL, D.M., SCULLY, S.P., HARRELSON, J.M., LAYFIELD, L.J, BEAN. J.M., PROSNITZ, L.R. & DEWHIRST, M.W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research, 56, 941.
8. BUSH, RS, JENKIN, R.D.T., ALLT, WE.C., BEALE, FA., BEAN, H., DEMBO, A.J. &. PRINGLE, J.F. (1978). Definitive evidence for hypoxic cells influencing cure in cancer therapy. British Journal of Cancer, 37(Suppl. III), 302.
9. CHAPLIN, D.J., DURAND, R.E & OLIVE, PL. (1986). Acute hypoxia in tumors: implications for modifiers of radiation effects. International Journal for Radiation Oncology Biology Physics, 12, 1279.
10. CHAPLIN, D.J., OLIVE, P.L. & DURAND, R E. (1987). Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Research, 47, 597.
11. CHAPMAN, JD. (1991). Measurement of tumour hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiotherapy and Oncology, Suppl. 20, 13.
12. CHAPMAN, J.D., FRANKO, A J. & SHARPLIN, J. (1981). A marker for hypoxic cells in tumours with potential clinical applicability. British Journal of Cancer, 43, 546.
13. CHAPMAN, J.D., BAER, K. & LEE, J. (1983). Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Research, 43, 1523.
14. CHAPMAN, J.D., LEE, J. & MEEKER, B.E. (1989). Cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. International Journal for Radiation Oncology Biology Physics, 16, 911.
15. CHAPMAN, JD., LEE, J. & MEEKER, B.E (1990). Adduct formation by 2-nitroimidazole drugs in mammalian cells: optimization of markers for tissue oxygenation. In Selective Activation of Drugs by Redox Processes. Adams, G.E., Breccia, A., Fielden, E.M.and Wardman, P. (eds). Plenum Press: New York.
16. 131I]iodoerythronitroimidazole. Journal Drug Targeting, 4, 31.
17. CLARKE, E.D. GOULDING, K.H. & WARDMAN, P (1982). Nitroimidazoles as anaerobic electron acceptors for xanthine oxidase. Biochemical Pharmacology, 31, 3237.
18. CLINE, J.M., THRALL, D.E., PAGE, R.L., FRANKO, A.J. & RALEIGH, J.A. (1990). Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. British Journal of Cancer, 62, 925.
19. CLINE, J.M., THRALL, D.E., ROSNER, G.L & RALEIGH, J.A (1994). Distribution of the hypoxia marker CCI-103F in canine tumors. International Journal for Radiation Oncology Biology Physics, 28, 921.
20. CLINE, J.M., ROSNER, G.L., RALEIGH, JA. & THRALL, D.E. (1997). Quantification of CCI-103F labeling heterogeneity in canine solid tumors. International Journal for Radiation Oncology Biology Physics, 37, 655.
21. COBB, L.M., HACKER, T. & NOLAN, J. (1990). NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole. British Journal of Cancer, 61, 524.
22. DENNIS, M F., STRATFORD, M.R., WARDMAN, P. & WATTS, M.E. (1985). Cellular uptake of misonidazole and analogues with acidic or basic functions. International Journal Radiation Oncology Biology Physics, 47, 629.
23. DOHERTY, J. & GRAHAM, D. (1989). The radiopharmacy. In Practical Nuclear Medicine. Sharp, P., Gemmell, H.G. & Smith, F.W. (eds), p. 71. IRL Press: Oxford.
24. EVANS, S.M., JENKINS, W.T, JOINER, B , LORD, E.M. & KOCH, C J (1996). 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Research, 56, 405.
25. 14C-misonidazole to hypoxic cells in V79 spheroids. British Journal of Cancer, 45, 694.
26. FRANKO, A.J., KOCH, CJ., GARRECHT, B.M., SHARPLIN, J. & HUGHES, D (1987). Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. Cancer Research, 47, 5367.
27. GRAEBER, T.G, OSMANIAN, C., JACKS, T., HOUSMAN, D.E., KOCH, C.J., LOWE, S.W & GIACCIA, A.J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88.
28. GROSHAR, D., MCEWAN, A.J., PARLIAMENT, M B., URTASUN, R.C., GOLBERG, L.E., HOSKINSON, M., MERCER, J.R., MANNAN, R.H., WIEBE, L.I. & CHAPMAN, J.D. (1993). Imaging tumor hypoxia and tumor perfusion. Journal of Nuclear Medicine, 34, 885.
29. GRUNBERG, E., BESKID, G., CLEELAND, R., DELORENZO, WE, TITSWORTH, E., SCHOLER, H.J., RICHLE, R. & BRENER, Z (1967). Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives. Antimicrobial Agents Chemotherapy, 7, 513.
30. HEIMBROOK, D.C. & SARTORELLI, A.C. (1986). Biochemistry of misonidazole reduction by NADPH-cytochrome c (p-450) reductase. Molecular Pharmacology, 29, 168.
31. 2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology, 26, 45.
32. HÖCKEL, M., VORNDRAN, B., SCHLENGER, K., BAUßMANN, E. & KNAPSTEIN, P.G. (1993b). Tumor Oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecology and Oncology, 51, 141.
33. HOCKEL, M., SCHLENGER, K., ARAL, B., MITZE, M., SCHAFFER, U. & VAUPEL. P (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56, 4509.
34. HODGKISS, RJ & WARDMAN, P. (1992). The measurement of hypoxia in tumours. British Journal of Radiology, Suppl. 24, 105.
35. HODGKISS, R.J., JONES, G., LONG, A., PARRICK. J., SMITH, KA., STRATFORD, M.R L. & WILSON, G.D. (1991). Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. British Journal of Cancer, 63, 119.
36. HODGKISS, R.J., PARRICK, J., PORSSA, M. & STRATFORD, M R L. (1994). Bioreductive markers for hypoxic cells: 2-nitroimidazoles with biotinylated 1-substituents. Journal of Medicinal Chemistry, 37, 4352.
37. HODGKISS, R.J., STRATFORD, M.R.L., DENNIS, M.F. & HILL, S.A (1995). Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration. British Journal of Cancer, 72, 1462.
38. HODGKISS, R.J. WEBSTER, L. & G.D WILSON, G.D. (1997). Measurement of hypoxia in vivo using a 2-nitromidazole (NITP). In Oxygen Transport to Tissues XIX, Proceedings of the 24th ISOTT Meeting, Dundee, 1996. Advances in Experimental Medicine and Biology, 428, 61.
39. 3H]misonidazole in cerebral ischemia. Stroke, 18, 168.
40. JOHNSON, G., III, NGUYEN, K.N., EDWARDS, B., ARCHER, C.M. & OKADA, R.D. (1995a). HL91-technetium-99m: effects of flow and hypoxia on the myocardial tissues of a new hypoxia avid imaging agent. Circulation, 92(Suppl. 1), 3801.
41. JOHNSON, G., III, NGUYEN, K.N., EDWARDS, B, ARCHER, C.M, & OKADA, R.D. (1995b). HL91-technetium-99m: uptake and retention of a new hypoxia avid imaging agent can differentiate ischemic viable from ischemic nonviable myocardium. Circulation, 92(Suppl. 1), 3791.
42. JOSEPH, P, JAISWAL, A.K., STOBBE, C.C. & CHAPMAN, JD. (1994). The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. International Journal for Radiation Oncology Biology Physics, 29, 351.
43. KOCH, C.J. (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Research, 53, 3992.
44. KOCH, C.J., STOBBE, C.C. & BAER, K.A. (1984). Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration. International Journal for Radiation Oncology Biology Physics, 10, 1327.
45. KOCH, C.J., EVANS, S.M. & LORD, E.M. (1995). Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-y1)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. British Journal of Cancer, 72, 869.
46. KOH, WJ., RASEY, J.S., EVANS, M.L., GRIERSON, J.R., LEWELLEN, T.K., GRAHAM, M.M., KROHN, K.A. & GRIFFIN, T.W. (1992). Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. International Journal for Radiation Oncology Biology Physics, 22, 199.
47. KOH, W.J., BERGMAN, K.S., RASEY, J.S., PETERSON, L.M., EVANS. M.L., GRAHAM, M.M., GRIERSON, J.R., LINDSLEY, K.L., LEWELLEN, T.K., KROHN, K.A & GRIFFIN, T.W. (1995). Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. International Journal for Radiation Oncology Biology Physics, 33, 391.
48. LARTIGAU, E. & GUICHARD, M (1995). Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure? International Journal of Radiation Biology, 67, 211.
49. LEE, J., SIEMANN, D.W., KOCH, C.J. & LORD, E.M (1996). Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. International Journal of Cancer, 67, 372.
50. 19F] magnetic resonance spectroscopy. Cancer Communications, 3, 133.
51. LINDER, K.E., CHAN, Y.W., CYR, J.E., MALLEY, M.F., NOWOTNIK, D.P. & NUNN, A.D. (1994). TcO(PnA-O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. Journal of Medicinal Chemistry, 37, 9.
52. LORD, E.M., HARWELL, L & KOCH, C.J. (1993). Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Research, 53, 5721.
53. MANNAN, R.H, SOMAYAJI, V.V, LEE, J., MERCER, J.R., CHAPMAN, J.D. & WIEBE, LI (1991). Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. Journal of Nuclear Medicine, 32, 1764.
54. MANNAN, R H., MERCER, J.R., WIEBE, L.I , KUMAR, P., SOMAYAJI, V.V. & CHAPMAN, J.D. (1992a). Radioiodinated azomycin pyranoside (IAZP): a novel non-invasive marker for the assessment of tumor hypoxia. Journal Nuclear Biology Medicine, 36, 60.
55. MANNAN, RH., MERCER, J.R., WIEBE, LI, SOMAYAJI, VV & CHAPMAN, J.D. (1992b). Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: a novel probe for the noninvasive assessment of tumor hypoxia. Radiation Research, 132, 368.
56. 3H]fluoromisonidazole in ischemic myocardium. Journal of Nuclear Medicine, 30, 194.
57. MARTIN, G.V., BISKUPIAK, J.E., CALDWELL. J.H., RASEY, JS & KROHN, KA. (1993). Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia [see comments]. Journal of Nuclear Medicine, 34, 918.
58. 2 inhibition of nitroreductase. Biochemical Biophysical Communications, 67, 1267.
59. MATHIAS, C.J., WELCH, M.J., KILBOURN, M R , JERABEK, PA , PATRICK. TB., RAICHLE, M.E., KROHN, KA., RASEY, J.S. & SHAW, D.W. (1987). Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. Life Science, 41, 199.
60. 19F magnetic resonance spectroscopy. International Journal for Radiation Oncology Biology Physics, 16, 925.
61. McMANUS, M.E., LANG, M.A., STUART, K. & STRONG, J (1982). Activation of misonidazole by rat liver microsomes and purified NADPH-cytochrome c reductase. Biochemical Pharmacology, 31, 547.
62. MILLER, G.G., BEST, M.W., FRANKO, A.J., KOCH, CJ. & RALEIGH, J.A (1989). Quantitation of hypoxia in multicellular spheroids by video image analysis. International Journal for Radiation Oncology Biology Physics, 16, 949.
63. MOORE, RB., CHAPMAN, J.D., MERCER, J.R , MANNAN, R.H., WIEBE, L.I., MCEWAN, A.J. & MCPHEE, M.S (1993). Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123- iodoazomycin arabinoside. Journal of Nuclear Medicine, 34, 405.
64. NG, C.K, SINUSAS, A.J., ZARET, B.L. & SOUFER, R. (1995). Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. Circulation, 92, 1261.
65. NORDSMARK, M., HOYER, M., KELLER, J., NIELSEN, O.S , JENSEN, O.M. & OVERGAARD, J (1996). The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. International Journal for Radiation Oncology Biology Physics, 35, 701.
66. OKADA, R.D., NGUYEN, K.N, STRAUSS, H.W. & JOHNSON, G.R. (1996). Effects of low flow and hypoxia on myocardial retention of technetium-99m BMS181321. European Journal of Nuclear Medicine, 23, 443.
67. OVERGAARD, J. (1992). Importance of tumour hypoxia in radiotherapy: a meta-analysis of controlled clinical trials. Radiotherapy and Oncology, 24, S64.
68. OVERGAARD, J (1994). Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncology Research, 6, 509.
69. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. British Journal of Cancer, 65, 90.
70. RALEIGH, J.A., FRANKO, A J., KOCH, C.J & BORN, J.L. (1985). Binding of misonidazole to hypoxic cells in monolayer and spheroid culture: evidence that a side-chain label is bound as efficiently as a ring label. British Journal of Cancer, 51, 229.
71. RALEIGH, J.A., MILLER, G.G., FRANKO, A.J., KOCH, CJ. FUCIARELLI, A.F & KELLEY, D.A. (1987). Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. British Journal of Cancer, 56, 395.
72. RALEIGH, J.A., ZEMAN, E.M., LA DINE, J.K., CLINE, J.M & THRALL, D E. (1993). Immunohistochemical detection of tumour hypoxia: pimonidazole. Abstracts of the 13th Radiation Research Society Meeting, P-31-8, 163.
73. RALEIGH, J.A., LA DINE, JK., CLINE, J.M & THRALL, D.E. (1994). An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours. British Journal of Cancer, 69, 66.
74. RASEY, JS., KROHN, KA, GRUNBAUM, Z, CONROY, P.J., BAUER, K. & SUTHERLAND, R.M. (1985). Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells. Radiation Research, 102, 76.
75. RASEY, J.S., HUFFMAN, J.M., SPENCE, A.M. & KROHN, K A. (1986). Hypoxia mediated binding of misonidazole in non-malignant tissue. International Journal for Radiation Oncology Biology Physics, 12, 1255.
76. RASEY, J.S., GRUNBAUM, Z., MAGEE, S., NELSON, N.J., OLIVE, P.L., DURAND, R.E. & KROHN, K.A. (1987). Characterization of radiolabelled fluoromisonidazole as a probe for hypoxic cells. Radiation Research, 111, 292.
77. RASEY, JS., KOH, W.J., GRIERSON, J.R., GRUNBAUM, Z. & KROHN, K.A. (1989). Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. International Journal for Radiation Oncology Biology Physics, 17, 985.
78. 18F]fluoromisonidazole: a pretherapy study of 37 patients. International Journal for Radiation Oncology Biology Physics, 36, 417.
79. ROJAS, A., JOINER, M C., HODGKISS, R.J, CARL, U., KJELLEN, E. & WILSON, G.D. (1992). Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys. International Journal for Radiation Oncology Biology Physics, 23, 361.
80. RUMSEY, W.L., CYR, J.E., RAJU N. & NARRA, R K (1993). A novel [99m]technetium-Iabeled nitroheterocycle capable of identification of hypoxia in heart. Biochemical and Biophysical Communications, 193, 1239.
81. RUMSEY, W.L, PATEL, B. & LINDER, KE. (1995). Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. Journal of Nuclear Medicine, 36, 632.
82. 3H]misonidazole by hypoxic rat liver. International Journal for Radiation Oncology Biology Physics, 10, 1365.
83. SMITH, GE. & ORSI, B.A. (1989). Nitroreductase activity of NADH dehydrogenase of the respiratory redox chain. Biochemical Journal, 257, 859.
84. STERN, S., HODGKISS, R.J & GUICHARD, M. (1996). Comparison of two techniques for detecting tumour hypoxia: a fluorescent immunochemical method and an in vitro colony assay. Radiotherapy and Oncology, 39, 129.
85. STONE, H.B , BROWN, J.M., PHILLIPS, T.L. & SUTHERLAND, R M. (1993). Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiation Research, 136, 422.
86. THOMLINSON, R.H. & GRAY, L H. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer, 9, 539.
87. 3H-misonidazole to solid human tumours as a measure of tumour hypoxia. International Journal for Radiation Oncology Biology Physics, 12, 1263.
88. 2 at the cellular level. British Journal of Cancer, 54, 453.
89. 14C-misonidazole binding in vivo technique. Proceedings of the 6th Conference on Chemical Modifiers of Cancer Treatment, 1-10-1-11.
90. VAN GEEL, I P., OPPELAAR, H., RIJKEN, P.F., BERNSEN, H.J., HAGEMEIER, N.E, VAN DER KOGEL, A.J., HODGKISS, R.J. & STEWART, F.A. (1996). Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. British Journal of Cancer, 73, 288.
91. VARGHESE, A J. & WHITMORE, G.F. (1980). Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Research, 40, 2165.
92. VARGHESE, A.J. & WHITMORE, GF (1983). Modification of guanine derivatives by reduced 2-nitroimidazoles. Cancer Research, 43, 78.
93. WALEH, N S., BRODY, M.D., KNAPP, M A , MENDONCA. H.L , LORD, E.M , KOCH, C.J., LADEROUTE, K.R. & SUTHERLAND, R.M (1995). Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Research, 55, 6222.
94. WALTON, M I. & WORKMAN, P (1987). Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochemical Pharmacology, 36, 887.
95. WARDMAN, P. (1978). The nitroimidazole family of drugs. British Journal of Venereal Diseases, 54, 69.
96. WARDMAN, P. & CLARKE, E.D. (1976). Oxygen inhibition of nitroreductase electron transfer from nitro radical-anions to oxygen. Biochemical Biophysics Research Communications, 69, 942.
97. WEBSTER, L. (1994). Hypoxia and Proliferation in Murine Tumour Models. PhD Thesis, University College, University of London.
98. WEBSTER, L., HODGKISS, R.J. & WILSON, G.D. (1995). Simultaneous triple staining for hypoxia, proliferation and DNA content in solid murine tumors. Cytometry, 21, 344.
99. WEBSTER, L., HODGKISS, R.J. & WILSON, G.D (1998). Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. British Journal of Cancer, 77, 227.
100. WIEBE, L.I. & STYPINSKI, D. (1996). Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. Journal of Nuclear Medicine, 40, 270.
101. YANG, D.J, WALLACE, S., CHERIF, A., LI, C., GRETZER, M.B., KIM, E.E & PODOLOFF, D.A (1995). Development of F-18-labelled fluoroerythronitroimidazole as a PET agent for imaging tumour hypoxia. Radiology, 194, 795.
102. ZEMAN, E.M., CALKINS, D.P., CLINK, JM., THRALL. D.E. & RALEIGH, J.A. (1993). The relationship between proliferative and oxygenation status in spontaneous canine tumours. International Journal for Radiation Oncology Biology Physics, 27, 891.